KPIs & Operating Metrics(New)
Growth Metrics

Teva Pharmaceutical Industries (TEVA) Finished Goods: 2010-2018

Historic Finished Goods for Teva Pharmaceutical Industries (TEVA) over the last 1 years, with Dec 2018 value amounting to $2.7 billion.

  • Teva Pharmaceutical Industries' Finished Goods fell 0.89% to $2.7 billion in Q4 2018 from the same period last year, while for Dec 2018 it was $2.7 billion, marking a year-over-year decrease of 0.89%. This contributed to the annual value of $2.7 billion for FY2018, which is 0.89% down from last year.
  • Teva Pharmaceutical Industries' Finished Goods amounted to $2.7 billion in Q4 2018, which was down 0.52% from $2.7 billion recorded in Q3 2018.
  • In the past 5 years, Teva Pharmaceutical Industries' Finished Goods registered a high of $2.8 billion during Q4 2016, and its lowest value of $2.0 billion during Q4 2015.
  • In the last 3 years, Teva Pharmaceutical Industries' Finished Goods had a median value of $2.7 billion in 2017 and averaged $2.7 billion.
  • In the last 5 years, Teva Pharmaceutical Industries' Finished Goods dropped by 11.65% in 2014 and then soared by 38.15% in 2016.
  • Over the past 5 years, Teva Pharmaceutical Industries' Finished Goods (Quarterly) stood at $2.3 billion in 2014, then fell by 9.61% to $2.0 billion in 2015, then spiked by 38.15% to $2.8 billion in 2016, then dropped by 5.05% to $2.7 billion in 2017, then dropped by 0.89% to $2.7 billion in 2018.
  • Its Finished Goods stands at $2.7 billion for Q4 2018, versus $2.7 billion for Q3 2018 and $2.7 billion for Q2 2018.